BioWorld

March 13, 2002

View Archived Issues

Myriad, Abbott Team In Deal To Diagnose, Treat Depression

Myriad Genetics Inc. entered a deal worth upward of $34 million with Abbott Laboratories Inc. to identify genes and drug targets for the diagnosis and treatment of depression. (BioWorld Today) Read More

Ricerca Licenses Cancer Gene; CRO Embraces New Paradigm’

Read More

Classic Mutant Mouse With Multi- Neuronal Disorders Shines Light On Potential Human Manipulation

Read More

Alexion, CuraGen Seek Cancer Targets For Drug Development

Read More

Phenomix’s Forward Genetics’ Gets $32M Funding Commitment

Read More

Other News To Note

Read More

Senomyx Raises $36.8M Privately To Fund Taste, Smell Programs

Read More